Skip to main content

Published locations for Ivosidenib leads to complete responses in 32% of IDH1-mutated relapsed/refractory AML

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Ivosidenib leads to complete responses in 32% of IDH1-mutated relapsed/refractory AML

User login

  • Reset your password
  • /content/ivosidenib-leads-complete-responses-32-idh1-mutated-relapsed/refractory-aml
  • /hematologynews/article/167147/aml/ivosidenib-leads-complete-responses-32-idh1-mutated-relapsed
  • /oncologypractice/article/167147/aml/ivosidenib-leads-complete-responses-32-idh1-mutated-relapsed
  • /hematology-oncology/article/167147/aml/ivosidenib-leads-complete-responses-32-idh1-mutated-relapsed